| 13.05 15:07 | dpa-AFX: Baxter: FDA Approves Expanded Indication For Clinolipid To Include Pediatric Patients |
| 13.05 14:50 | dpa-AFX: *BAXTER GETS FDA APPROVAL OF CLINOLIPID NEONATAL AND PEDIATRIC INDICATION |
| 07.05 14:35 | dpa-AFX: *BAXTER INTL. DECLARES QUARTERLY CASH DIVIDEND OF $0.29, PAYABLE JULY 1, RECORD MAY 31 |
| 02.05 14:05 | dpa-AFX: Baxter Sees Q2 Adj. EPS In Line Or Below Market; Lifts FY24 View; Stock Down In Pre-market |
| 02.05 13:26 | dpa-AFX: Baxter International Inc. Q1 Profit Decreases, but beats estimates |
| 02.05 13:24 | dpa-AFX: *BAXTER INTERNATIONAL Q1 WORLDWIDE SALES FROM CONT. OPS. UP 2% TO $3.59 BLN |
| 02.05 13:24 | dpa-AFX: *BAXTER INTERNATIONAL Q1 EPS $0.07 VS. $0.09 LAST YEAR |
| 02.05 13:19 | dpa-AFX: *BAXTER Q1 EPS FROM CONT. OPS. $0.07; ADJ PS FROM CONT. OPS. $0.65 |
| 02.05 12:03 | dpa-AFX: Baxter International Q1 24 Earnings Conference Call At 8:30 AM ET |
| 13.02 00:32 | dpa-AFX: *BAXTER INTERNATIONAL INC. (BAX) DECLARES QUARTERLY DIVIDEND OF $ 0.29, RECORD DATE 3/1/2024 |
| 08.02 15:43 | dpa-AFX: Baxter International Inc. Q4 Profit Increases, Adjusted Earnings Beat Estimates |
| 08.02 13:27 | dpa-AFX: *BAXTER EXPECT Q1 SALES GROWTH OF APPROX. 1%, ADJ. EPS OF $0.59 TO $0.62 |
| 08.02 13:26 | dpa-AFX: *BAXTER EXPECT FY24 SALES GROWTH OF APPROX. 2%, ADJ. EPS OF $2.85 TO $2.95 |
| 08.02 13:26 | dpa-AFX: Baxter International Inc. Q4 Profit Increases, but misses estimates |
| 08.02 13:25 | dpa-AFX: *BAXTER Q4 ADJ. EPS FROM CONT. OPS. $0.88 VS. $0.78 LAST YEAR |
| 08.02 13:24 | dpa-AFX: *BAXTER Q4 NET SALES $3.885 BLN VS. $3.745 BLN LAST YEAR |
| 08.02 13:23 | dpa-AFX: *BAXTER Q4 OPERATING INCOME $329 MLN VS. $290 MLN LAST YEAR |
| 08.02 13:23 | dpa-AFX: *BAXTER Q4 NET INCOME $245 MLN VS. $181 MLN LAST YEAR |
| 08.02 13:18 | dpa-AFX: *BAXTER Q4 EPS FROM CONT. OPS. $0.14 VS $0.28 LAST YEAR |
| 08.02 12:03 | dpa-AFX: Baxter International Q4 23 Earnings Conference Call At 8:30 AM ET |
|
|
